Zhiming Li

University of Electronic Science and Technology of China — China

Medicine · Health Sciences

29h-index3.4kcitations344works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(233), Chronic Lymphocytic Leukemia Research(105), Viral-associated cancers and disorders(55), CNS Lymphoma Diagnosis and Treatment(43), CAR-T cell therapy research(42)

Publications344 total

An Accurate and Fast Method for Solving RCS of Honeycomb Structures Based on the Global GPBICGSTAB( <i>l</i> )-TDS Algorithm
IEEE Antennas and Wireless Propagation Letters·2025
Supplementary Figure S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025Open Access
Supplementary Table S4 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025Open Access
Supplementary Table S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025Open Access
Supplementary Table S5 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025Open Access
Supplementary Table S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025Open Access
Supplementary Figure S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025Open Access
Supplementary Figure S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025Open Access
Supplementary Table S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025Open Access
Supplementary Table S6 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025Open Access
First-line selinexor plus R-CHOP for high-risk GCB-subtype diffuse large B-cell lymphoma: A multi-center, single-arm, Phase II trial
Blood·2025Open Access
Diagnostic value of super-resolution ultrasound imaging in differentiating benign and malignant BI-RADS-4 breast lesions
Frontiers in Oncology·2025Open Access
MA06.04 Improving Preoperative ctDNA Detection in NSCLC Through Mechanistic Profiling and Multiregion-Informed Customization
Journal of Thoracic Oncology·2025· 1 cited
Supplement 5 from Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial
2025Open Access
Supplement 3 from Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial
2025Open Access
Data from Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial
2025Open Access
Supplement 2 from Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial
2025Open Access
Supplement 1 from Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial
2025Open Access
Supplement 4 from Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial
2025Open Access
2987O Efficacy and safety of dabrafenib plus trametinib (D+T) in patients with radioactive iodine (RAI)-refractory BRAF V600-mutant differentiated thyroid cancer (DTC)
Annals of Oncology·2025
page 1 of 18Next →

Frequent Co-authors

Yi Xia(18), Wen-Qi Jiang(17), Hui-Qiang Huang(12), Yu Wang(11), Panpan Liu(10), Jia-Jia Huang(10), Peng Sun(9), Tong-Yu Lin(9), Xi-Wen Bi(8), Man Nie(6), Ya-Jun Li(6), Huilai Zhang(6), Zhong-Jun Xia(6), Wenqi Jiang(5), Xiwen Bi(4), Wei Zhao(4), Hang Yang(4), Haiyan Yang(4), Ying-Jie Zhu(3), Weicheng Ren(3)